Barinthus Biotherapeutics Zukünftiges Wachstum

Future Kriterienprüfungen 0/6

Barinthus BiotherapeuticsDer Gewinn des Unternehmens wird voraussichtlich um 1.7% pro Jahr sinken, während der Jahresumsatz voraussichtlich um 2% pro Jahr wachsen wird. Der Gewinn pro Aktie wird voraussichtlich sinken um 1.7% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich -162.7% betragen.

Wichtige Informationen

-1.8%

Wachstumsrate der Gewinne

-1.8%

EPS-Wachstumsrate

Biotechs Gewinnwachstum	28.5%
Wachstumsrate der Einnahmen	2.4%
Zukünftige Eigenkapitalrendite	-173.7%
Analystenabdeckung	Low
Zuletzt aktualisiert	25 Sep 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Is Barinthus Biotherapeutics (NASDAQ:BRNS) In A Good Position To Invest In Growth?

Aug 31

Here's Why We're Watching Barinthus Biotherapeutics' (NASDAQ:BRNS) Cash Burn Situation

Apr 05

Analysts Just Made An Incredible Upgrade To Their Vaccitech plc (NASDAQ:VACC) Forecasts

Aug 15

Vaccitech plc Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

Aug 13

Vaccitech GAAP EPS of $0.41, revenue of $17.06M

Aug 09

Growth Investors: Industry Analysts Just Upgraded Their Vaccitech plc (NASDAQ:VACC) Revenue Forecasts By 51%

May 19

Vaccitech: Aiming For A Cure In Chronic Hepatitis B

Apr 03

Vaccitech: The Next Big Vaccine Trade

Jun 27

Vaccitech EPS misses by $0.69, beats on revenue

Jun 14

Gewinn- und Umsatzwachstumsprognosen

NasdaqGM:BRNS - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	1	-60	N/A	N/A	3
12/31/2025	N/A	-65	N/A	N/A	3
12/31/2024	N/A	-67	N/A	N/A	3
6/30/2024	N/A	-64	-55	-55	N/A
3/31/2024	0	-71	-63	-60	N/A
12/31/2023	1	-73	-56	-51	N/A
9/30/2023	7	-77	-49	-43	N/A
6/30/2023	13	-55	-28	-20	N/A
3/31/2023	30	-15	-19	-11	N/A
12/31/2022	45	5	-21	-14	N/A
9/30/2022	38	11	-17	-11	N/A
6/30/2022	32	-1	-29	-25	N/A
3/31/2022	15	-33	-33	-31	N/A
12/31/2021	0	-51	-34	-33	N/A
9/30/2021	1	-46	-30	-30	N/A
6/30/2021	4	-41	-29	-28	N/A
3/31/2021	4	-29	-15	-15	N/A
12/31/2020	5	-18	-11	-11	N/A
12/31/2019	7	-21	-19	-19	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: BRNS wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Ertrag vs. Markt: BRNS wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Hohe Wachstumserträge: BRNS wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Einnahmen vs. Markt: BRNS wird im nächsten Jahr voraussichtlich keine Einnahmen haben.

Hohe Wachstumseinnahmen: BRNS wird im nächsten Jahr voraussichtlich keine Einnahmen haben.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: BRNS wird voraussichtlich in 3 Jahren unrentabel sein.

Barinthus Biotherapeutics Zukünftiges Wachstum

Future Kriterienprüfungen 0/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Consensus revenue estimates increase by 29%

Consensus revenue estimates decrease by 20%, EPS upgraded

Price target decreased by 24% to US$9.31

Consensus revenue estimates increase by 26%

Consensus revenue estimates decrease by 53%, EPS upgraded

Consensus revenue estimates decrease by 28%

Recent updates

Is Barinthus Biotherapeutics (NASDAQ:BRNS) In A Good Position To Invest In Growth?

Barinthus Biotherapeutics plc Plans to Priority on the Development of VTP-300 in Chronic Hepatitis B Virus Infection, or CHB, and VTP-1000 in Celiac Disease

Barthus Biotherapeutics plc Announces Updated Data from Two Clinical Trials in People with Chronic Hepat B

First quarter 2024 earnings released: US$0.40 loss per share (vs US$0.48 loss in 1Q 2023)

Barinthus Biotherapeutics plc Appoints Leon Hooftman as Chief Medical Officer, Effective from Beginning of June 2024

BarinthuBarinthus Biotherapeutics plc Announces Topline Data from Phase 1b/2 APOLLO Trial of VTP-200 in Persistent High-Risk Human Papillomavirus (HPV) Infections

Here's Why We're Watching Barinthus Biotherapeutics' (NASDAQ:BRNS) Cash Burn Situation

New minor risk - Share price stability

Consensus revenue estimates increase by 29%

Barinthus Biotherapeutics plc, Annual General Meeting, May 10, 2024

New major risk - Revenue size

Full year 2023 earnings released: US$1.91 loss per share (vs US$0.14 profit in FY 2022)

Insufficient new directors

New minor risk - Market cap size

Consensus revenue estimates decrease by 20%, EPS upgraded

Arbutus Biopharma Corporation and Barinthus Biotherapeutics plc Present Preliminary Data from Phase 2A Clinical Trial Combining Imdusiran with VTP-300 at AASLD

Third quarter 2023 earnings released: US$0.36 loss per share (vs US$0.22 profit in 3Q 2022)

Vaccitech plc(NasdaqGM:VACC) dropped from NASDAQ Composite Index

Price target decreased by 24% to US$9.31

Consensus revenue estimates increase by 26%

Consensus revenue estimates decrease by 53%, EPS upgraded

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Vaccitech plc Announces Retirement of Margaret Marshall as Chief Medical Officer

We Think Vaccitech (NASDAQ:VACC) Can Afford To Drive Business Growth

Vaccitech plc Announces Positive Final Data EASL Congress for Phase 1B/2 HBV002 Study in Adults with Chronic Hepatitis B

Vaccitech plc Doses First Patient in Pca001, A Prostate Cancer Phase 1/2 Clinical Trial of Vtp-850

Consensus revenue estimates decrease by 28%

First quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Consensus revenue estimates increase by 12%, EPS downgraded

Price target decreased by 28% to US$14.33

Investor sentiment improves as stock rises 23%

Investor sentiment deteriorates as stock falls 17%

Vaccitech Appoints Nadège Pelletier as Chief Scientific Officer

Vaccitech's (NASDAQ:VACC) Earnings Are Of Questionable Quality

Consensus forecasts updated

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Consensus forecasts updated

Vaccitech plc Provides Update on Ongoing VTP-300 Phase 1b/2a Trial Showing Sustained Reductions of HBsAg in Patients with Chronic Hepatitis B

Vaccitech plc Doses First Patients in HBV003, a Phase 2b Clinical Trial of VTP-300 Immunotherapeutic Candidate for Chronic HBV Patients

Vaccitech plc Announces Publication of Research in Preclinical Animal Models Demonstrating the Potential of Vaccitech’s SNAPvax

Vaccitech plc Promotes Gemma Brown as Chief Financial Officer

Vaccitech promotes Gemma Brown to CFO

Consensus revenue estimates increase by 61%

Analysts Just Made An Incredible Upgrade To Their Vaccitech plc (NASDAQ:VACC) Forecasts

Vaccitech plc Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

Price target decreased to US$19.50

Vaccitech GAAP EPS of $0.41, revenue of $17.06M

Vaccitech plc Announces an Update to the Interim Analysis of Safety and Efficacy Data from the HBV002 Study

Arbutus Biopharma Corporation and Vaccitech plc Dose First Patient in Phase 2a Clinical Trial Combining Therapies for the Treatment of Chronic Hepatitis B Virus

Growth Investors: Industry Analysts Just Upgraded Their Vaccitech plc (NASDAQ:VACC) Revenue Forecasts By 51%

Consensus revenue estimates increase by 51%

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

Vaccitech plc, Annual General Meeting, Jun 15, 2022

Less than half of directors are independent

Consensus forecasts updated

Vaccitech: Aiming For A Cure In Chronic Hepatitis B

Less than half of directors are independent

Consensus forecasts updated

Consensus forecasts updated

Vaccitech plc Announces First Patient Dose in Phase I/Iia Trial of Lung Cancer Immunotherapy Vaccine

Vaccitech plc (NasdaqGM:VACC) acquired Avidea Technologies for $40 million.

Third quarter 2021 earnings released: US$0.13 loss per share

Vaccitech: The Next Big Vaccine Trade

Vaccitech EPS misses by $0.69, beats on revenue

Vaccitech plc has completed an IPO in the amount of $110.5 million.

Gewinn- und Umsatzwachstumsprognosen

Analystenprognosen zum zukünftigen Wachstum